Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc. (NYSE: BAX), reported continued progress on the Phase 1/2 open-label clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE